m+Medelevator.RU
← Поиск публикаций
Molecular therapy. Nucleic acids · 2025

Integrated multi-omics profiling uncovers miRNA-guided regulatory networks after spinal cord injury in rats.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Klassen Ruslan A, Chytilova Sarka, Arzhanov Ivan, Zucha Daniel, Rohlova Eva, Androvic Peter, Abaffy Pavel, Urdzikova-Machova Lucia, Kubista Mikael, Romanyuk Nataliya, Valihrach Lukas

Аннотация

Spinal cord injury (SCI) is a debilitating condition with no effective treatment. The injury triggers a complex cascade of molecular and cellular events that drive both damage and repair processes. To explore these mechanisms, we performed a comprehensive multi-omics analysis in a rat compression model of SCI, focusing on the acute phase. Transcriptomic profiling revealed extensive gene dysregulation, highlighting early inflammation, neuronal death, and synaptic dysfunction, followed by the initiation of reparative processes. Cell type composition analysis showed a rapid infiltration of peripheral immune cells; activation of microglia; and loss of neurons, astrocytes, and oligodendrocytes. Importantly, we provide experimental support for predicted microRNA (miRNA)-mRNA-protein interactions, offering a foundation for further mechanistic studies. miRNA profiling uncovered a highly dysregulated miRNA landscape, with the miR-17∼92 cluster emerging as a key regulator of neurogenesis, synaptic activity, and cell survival. Integrative miRNA-mRNA-protein analysis identified potential therapeutic targets, including miR-20a, whose inhibition in vitro supported neurogenesis and reduced apoptosis under oxidative stress. Our findings provide new insights into the molecular mechanisms of SCI and highlight miRNAs as potential targets for therapeutic intervention.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты